Caligan Partners LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001727492
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2025 · 17 positions · Total reported value $520.17M · Top-10 concentration 93.0% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 41.9% · 5 new · 3 cut · 5 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +38.3% · vs SPY +23.5% · Prev Value $1.30B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2025 13F filing, Caligan Partners LP disclosed 17 equity positions with a combined reported value of $520.17M. The filing implies a focused portfolio: its ten largest positions account for 93.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2025 were VRNA ($135.90M), LQDA ($101.16M), EXEL ($67.25M). By sector, the heaviest allocations are Health Care 65.2%, Other 34.8%. Versus the prior quarter, allocation shifted toward Other (+5.2pp) and away from Health Care (-5.2pp).
Versus the prior quarter, Caligan Partners LP opened 5 new positions, trimmed 3 and fully exited 5, a turnover rate of 41.9% of positions. The portfolio's overlap with the prior quarter was 83% of names.
The largest new positions opened in Q2 2025 were SLS ($5.04M), AURA ($1.25M).
Of the 5 positions fully exited versus the prior quarter, the largest were SAGE ($24.27M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2025)
- SLS SELLAS LIFE SCIENCES GROUP I · $5.04M
- AURA AURA BIOSCIENCES INC · $1.25M
Fully Exited (vs previous quarter)
- SAGE SAGE THERAPEUTICS INC · prev qtr: $24.27M
Insider Transactions (Form 4)
Latest Caligan Partners LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-16 | Award | Liquidia Corp | 5,882 | — | SEC filing |
| 2026-05-19 | Buy | Liquidia Corp | 5,300 | $59.98 | SEC filing |
| 2026-05-19 | Sell | Liquidia Corp | 5,300 | $59.98 | SEC filing |
Fund Profile
Caligan Partners LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 26 US equity positions with a combined value of $1.71B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-113810 (status: Approved), registered 2018-08-10
- Regulatory AUM (Form ADV): $1.30B as of 2026-05-29
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 3 private funds, of which 3 hedge funds
- Website: caliganpartners.com
Portfolio Structure
- 26 positions · $1.71B reported value (Q2 2026)
- Top 10 holdings = 81.5% of reported value
- Largest position: LQDA (LIQUIDIA CORPORATION) at 37.8%
- Average position size: $65.78M
Sector Tilt
- Health Care 99.1%
- (classified holdings cover 99% of value)
Quarterly Activity
- Q2 2026: 5 new, 8 added, 3 reduced, 5 exited
- 10 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
1.44M | $135.90M | 26.13% | Hold | |
| 2 |
|
8.12M | $101.16M | 19.45% | Hold | |
| 3 |
|
1.53M | $67.25M | 12.93% | Hold | |
| 4 |
|
1.07M | $35.63M | 6.85% | Add | |
| 5 |
|
657.00K | $34.56M | 6.64% | Add | |
| 6 |
|
3.34M | $30.78M | 5.92% | Add | |
| 7 |
|
2.02M | $27.29M | 5.25% | Reduce | |
| 8 |
|
636.84K | $23.43M | 4.50% | Add | |
| 9 |
|
1.44M | $15.18M | 2.92% | Hold | |
| 10 |
|
1.67M | $12.81M | 2.46% | Add | |
| 11 |
|
2.34M | $10.57M | 2.03% | Hold | |
| 12 |
|
1.54M | $6.88M | 1.32% | Add | |
| 13 |
|
638.91K | $5.72M | 1.10% | Reduce | |
| 14 |
|
2.30M | $5.04M | 0.97% | New | |
| 15 |
|
9.24M | $4.90M | 0.94% | Add | |
| 16 |
|
189.95K | $1.82M | 0.35% | Add | |
| 17 |
|
200.00K | $1.25M | 0.24% | New | |
FAQ
What did Caligan Partners LP buy in 2025-Q2?
In its 2025-Q2 13F filing, Caligan Partners LP reported 17 equity positions worth $520.17M in aggregate; its largest disclosed positions were VRNA ($135.90M), LQDA ($101.16M), EXEL ($67.25M).
How large is Caligan Partners LP's portfolio?
Caligan Partners LP reported $520.17M of long equity holdings across 17 positions as of 2025-Q2. Top-10 holdings account for 93.0% of reported value.
What is Caligan Partners LP's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.